Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 7/20 | 0.39 |
| ▸ | CTSL | P07711 | 6/20 | 0.39 |
| ▸ | CTSV | O60911 | 5/20 | 0.37 |
| ▸ | CTSB | P07858 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811407 | 1.00 | CTSK (0.50) | CTSKPKMFFAR2CTSSCTSL | |
| SCHEMBL6404414 | 1.00 | CTSK (0.50) | CTSKPKMFFAR2CTSSCTSL | |
| SCHEMBL4811438 | 1.00 | CTSK (0.50) | CTSKPKMFFAR2CTSSCTSL | |
| SCHEMBL6215913 | 1.00 | CTSK (0.50) | CTSKPKMFFAR2CTSSCTSL | |
| SCHEMBL4811319 | 1.00 | CTSK (0.50) | CTSKPKMFFAR2CTSSCTSL | |
| SCHEMBL6406209 | 0.86 | FFAR2 (0.39) | CTSKPKMFFAR2CTSSCTSL | |
| SCHEMBL6405415 | 0.86 | FFAR2 (0.39) | CTSKPKMFFAR2CTSSCTSL | |
| SCHEMBL6403784 | 0.86 | FFAR2 (0.39) | CTSKPKMFFAR2CTSSCTSL | |
| SCHEMBL14105190 | 0.85 | CTSK (0.50) | CTSKPKMCTSSCTSLCTSV | |
| SCHEMBL4820693 | 0.85 | CTSK (0.50) | CTSKPKMCTSSCTSLCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | CTSK 1/4885PKM 230/4885FFAR2 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.